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Abstract
Aims/hypothesis This study aimed to investigate the associa-
tions of plasma levels of the pro-inflammatory cytokine high-
mobility group box 1 (HMGB1) with incident cardiovascular
disease (CVD) and all-cause mortality in patients with type 1
diabetes.
Methods We prospectively followed 165 individuals with
diabetic nephropathy and 168 individuals with persistent nor-
moalbuminuria who were free of CVD at study entry and in
whom levels of HMGB1 and other cardiovascular risk factors
were measured at baseline.
Results During the course of follow-up (median, 12.3 years
[interquartile range, 7.8–12.5]), 80 patients died, 82 suffered
a fatal (n046) and/or non-fatal (n053) CVD event. After
adjustment for age, sex, case–control status and other risk
factors, patients with higher levels of loge HMGB1 had a
higher incidence of fatal and non-fatal CVD and all-cause
mortality: HR 1.55 (95% CI 0.94, 2.48) and HR 1.86 (95%
CI 1.18, 2.93), respectively. Further adjustments for differ-
ences in markers of low-grade inflammation, endothelial
and renal dysfunction and arterial stiffness did not attenuate
these associations because plasma levels of HMGB1 were
not independently associated with these variables.
Conclusions/interpretation In patients with type 1 diabetes,
higher levels of plasma HMGB1 are independently associ-
ated with a higher risk of all-cause mortality and, to a lesser
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extent, with a higher incidence of CVD. Larger studies are
needed to ascertain more definitely the role of HMGB1 in
the development of vascular complications in diabetes.
Keywords All-cause mortality . Cardiovascular disease .
High-mobility group box 1 . Type 1 diabetes mellitus
Abbreviations
CVD Cardiovascular disease
HMGB1 High-mobility group box 1
LGI Low-grade inflammation
MAP Mean arterial pressure
PP Pulse pressure
RAGE Receptor for AGEs
sRAGE Soluble receptor for AGEs
Introduction
The pathophysiological mechanisms linking hyperglycaemia
to the development of cardiovascular complications in
patients with diabetes mellitus are not completely clear. One
proposed mechanism involves AGEs and the receptor for
AGEs (RAGE) [1]. Besides AGEs, RAGE can also be acti-
vated by high-mobility group box 1 (HMGB1) [2].
Extracellular HMGB1 released from necrotic cells and/or
from immune cells upon inflammatory stimulation functions as
a pro-inflammatory cytokine, which elicits pro-inflammatory
responses from macrophages and endothelial cells [2]. The
extracellular effects of HMGB1 are mediated by its binding
to RAGE, and also by its binding to the receptors of the toll-
like receptor family [2]. HMGB1-induced production of in-
flammatory cytokines and adhesion molecules could contrib-
ute to low-grade inflammation (LGI), endothelial and renal
dysfunction and arterial stiffening, all of which may partially
explain the increased incidence of cardiovascular disease
(CVD) in individuals with diabetes.
We therefore investigated, in a 12 year prospective study of
patients with type 1 diabetes, first, the extent to which
HMGB1 levels are associated with incident fatal and non-
fatal CVD as well as all-cause mortality, and second the
potential mediating role of markers of LGI, endothelial and
renal dysfunction and/or arterial stiffness (i.e. pulse pressure).
Methods
Study design and population We examined 199 patients
with diabetic nephropathy (defined according to clinical
criteria, i.e. persistent macroalbuminuria [>300 mg/24 h]
in at least two out of three previous consecutive 24 h urine
collections, the presence of diabetic retinopathy and the
absence of other kidney or urinary tract disease) and 192
with persistent normoalbuminuria (i.e. urinary excretion
rate <30 mg/24 h) who were recruited, in 1993, from the
outpatient clinic at the Steno Diabetes Center for a pro-
spective observational study, as described in detail else-
where [1]. Briefly, all patients were followed up to the
last visit to the Center, until 1 September 2006, death
(n082) or emigration (n03). The study was approved by
the local ethics committee in accordance with the Helsinki
Declaration, and all patients gave their informed written
consent.
Main determinant Baseline levels of plasma HMGB1 were
measured in duplicate with a commercially available enzyme-
linked immunosorbent assay kit (Shino-Test Corporation,
Tokyo, Japan) and the intra- and inter-assay coefficients of
variation were 4.0% and 11.0%, respectively.
Outcomes Study outcomes were a combined endpoint of
fatal and non-fatal CVD, and all-cause mortality [1].
Statistical analyses All analyses were performed using
SPSS version 15.0 (SPSS, Chicago, IL, USA). Variables
with a skewed distribution were loge transformed prior to
further analyses. Comparisons of baseline characteristics
between groups were performed with Student’s t or χ2 tests,
as appropriate.
We used linear regression to investigate the cross-
sectional associations between HMGB1 and other cardio-
vascular risk factors, and Cox proportional hazards regres-
sion to investigate the associations of plasma HMGB1
with incident CVD and all-cause mortality. These analyses
were adjusted for age, sex, duration of diabetes and case–
control status, and adjusted further for other cardiovascu-
lar risk factors and use of medication (i.e. potential con-
founders). Other adjustments included markers of LGI,
endothelial dysfunction, renal dysfunction and pulse pres-
sure (PP) (i.e. potential mediators) to ascertain the extent
to which any such marker(s) could attenuate (i.e. explain)
the strength of the association between HMGB1 and study
endpoints.
A detailed description of measurement of study out-
comes, potential confounders and mediators is given in the
electronic supplementary material (ESM) Methods.
Results
We excluded 17 patients for whom follow-up data were not
obtained, ten with missing data on baseline biomarker lev-
els, seven with end-stage renal failure and 24 with prior
CVD at baseline. Results reported herein thus refer to 333
patients (165 with nephropathy and 168 with persistent
normoalbuminuria at baseline).
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During the course of follow-up (median: 12.3 years
[interquartile range (IQR) 7.8–12.5]), 80 individuals
(24.0%) died, 82 (24.6%) suffered a fatal (n046) and/or
non-fatal (n053) CVD event. Individuals with incident
CVD or who died in the course of follow-up had a more
adverse atherosclerotic risk profile at baseline (ESM Table 1),
although their median levels of HMGB1 (unadjusted for study
covariates) did not differ significantly from the levels of those
who remained free of CVD or were still alive: 0.77 ng/ml
(IQR 0.62–0.95) vs 0.77 (IQR 0.61–1.03) and 0.78 (IQR
0.64–0.99) vs 0.77 (0.60–1.01), respectively. However, after
adjustments for age, sex, duration of diabetes, case–control
status, HbA1c, BMI, smoking status, total cholesterol, mean
arterial pressure (MAP) and use of medication, their baseline
levels of HMGB1 were indeed increased such that higher
levels of HMGB1 (loge-transformed) were associated with
a higher incidence of fatal and non-fatal CVD (HR 1.55
[95% CI 0.96, 2.51]) and all-cause mortality (HR 1.86
[95% CI 1.18, 2.93]) (Table 1, model 5, Fig. 1a, b). The
magnitude of the associations between HMGB1 and study
outcomes increased and were significant only after covariate
adjustments, due to net negative confounding mainly by age,
HbA1c and total cholesterol, all of which were associated
inversely with HMGB1 but positively with study outcomes
(ESM Tables 2 and 3).
The adverse associations between HMGB1 and study
outcomes were not appreciably attenuated after further
adjustments for markers of LGI, endothelial and renal
dysfunction and PP (models 6a–d), because HMGB1 was
not independently associated with these variables (ESM
Table 4). Further adjustment for AGEs or soluble RAGE
(sRAGE) did not appreciably change the effect estimates
either (models 7a,b).
Additional analyses We also investigated the associations
between HMGB1 and study outcomes stratified by case–con-
trol status. The effect estimates seemed stronger in the group of
patients with normoalbuminuria (HR 4.17 [95% CI 0.75, 2.17]
for fatal and non-fatal CVD and HR 7.64 [95% CI 1.91, 30.60]
for all-cause mortality) than nephropathy (1.28 [95% CI 0.75,
2.17] and 1.59 [95% CI 0.98, 2.61], respectively), but did not
differ significantly between the groups (p interactions00.177
and 0.142, respectively). These data should be interpreted with
caution and may not justify an interpretation of true differences
between the groups because these analyses were underpow-
ered (only 20 CVD events and 17 all-cause deaths in the
normoalbuminuria group).
Discussion
The main findings of this study are that, in patients with type
1 diabetes, and after adjustments for confounders, higher
levels of plasma HMGB1 are associated with a higher
incidence of all-cause mortality and also, though to a lesser
extent, fatal and non-fatal CVD.
Table 1 Associations between plasma loge HMGB1 and incident fatal and non-fatal CVD and all-cause mortality (n0333)
Model: adjustments Fatal and non-fatal CVD All-cause mortality
HR 95% CI p value HR 95% CI p value
1: – 1.11 0.68, 1.79 0.689 1.34 0.84, 2.15 0.221
2: age and sex 1.27 0.78, 2.09 0.323 1.62 1.00, 2.62 0.049
3: model 2+case–control status, duration of diabetes and HbA1c 1.37 0.86, 2.20 0.186 1.65 1.06, 2.57 0.028
4: model 3+MAP, BMI, smoking status and total cholesterol 1.47 0.91, 2.36 0.113 1.72 1.08, 2.74 0.022
5: model 4+use of anti-hypertensive medicationa 1.55 0.96, 2.51 0.073 1.86 1.18, 2.93 0.008
6a: model 5+LGI scoreb 1.50 0.93, 2.43 0.095 1.81 1.15, 2.87 0.011
6b: model 5+endothelial dysfunction scorec 1.55 0.96, 2.51 0.073 1.81 1.14, 2.87 0.012
6c: model 5+eGFRMDRD and loge UAE 1.54 0.96, 2.45 0.071 1.80 1.14, 2.84 0.011
6d: model 5+PP 1.49 0.92, 2.42 0.105 1.80 1.14, 2.85 0.012
7a: model 5+AGE scored 1.52 0.94, 2.46 0.087 1.78 1.12, 2.82 0.014
7b: model 5+loge sRAGE
e 1.59 0.97, 2.61 0.063 1.86 1.17, 2.97 0.009
HR per each unit increase in loge HMGB1 levels at baseline
a Includes patients discontinuing medication before the baseline assessment
b Score comprising levels of C-reactive protein, secreted phospholipase A2 and IL-6
c Score comprising levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1
d Score comprising levels of protein-bound Nε -(carboxyethyl)lysine, Nε -(carboxymethyl)lysine and pentosidine
e Analyses confined to 331 individuals because of missing data for two individuals
eGFR, estimated GFR; MDRD, Modification of Diet in Renal Disease equation; UAE, urinary albumin excretion rate
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These findings are in agreement with three studies that
have reported positive associations of HMGB1 with coro-
nary artery disease [3, 4], heart failure [5] and mortality
related to heart disease [5] in patients with and without type
2 diabetes, though these were limited by their cross-
sectional study design [3–5] or short follow-up period [5].
The adverse role of elevated HMGB1 levels is supported by
observations at the molecular level showing that fatty
streaks and fibrofatty lesions contain more macrophages
with cytoplasmic and nucleic HMGB1 compared with nor-
mal intima [6], and that HMGB1 is also expressed by
activated vascular smooth muscle cells in more advanced
atherosclerotic lesions [7]. Furthermore, neutralising HMGB1
attenuated the development of atherosclerosis in an animal
model of atherosclerosis [8]. HMGB1 has been linked not
only to diabetes [4] and CVD [3–5], but also to inflammatory
diseases and cancer [9], which may explain the stronger
association with all-cause mortality than with CVD observed
in the present study.
While investigating the associations between HMGB1
and traditional risk factors we found positive associa-
tions with smoking but inverse associations with age,
HbA1c and cholesterol. Indeed, a net negative confound-
ing effect explained why, after adjustments for these
(and other) confounders, the adverse associations be-
tween HMGB1 and study outcomes were strengthened
and became statistically significant. The reasons for the
inverse associations between HMGB1 and some risk
factors are unclear and need to be further investigated.
Still, our study illustrates the importance of accounting
for confounding when examining the potential value of
a biomarker in outcome prediction. We did not find
independent associations between HMGB1 and LGI,
endothelial and renal dysfunction or PP, mechanisms
that could explain the increased CVD and mortality risk
associated with HMGB1. Given that we examined a
selection of biomarkers of these processes, we cannot
fully rule out their potential mediating role, but our
findings suggest that these pathophysiological mecha-
nisms and HMGB1 may constitute distinct pathways
leading to poorer outcome in these patients.
There are limitations to our study. First, measures of
HMGB1 and other biomarkers were taken at baseline
only. Second, an inter-assay variation lower than 11%,
as obtained in our HMGB1 measures, may enable more
precise estimates of the associations examined. Third,
we have recently shown that in patients with type 1
diabetes (EURODIAB study) serum HMGB1 was not
associated with prevalent CVD [10]. Apart from the
difference in study design (cross-sectional vs prospec-
tive), the apparent discrepancy with the positive associ-
ation between plasma HMGB1 and incident CVD
observed in the present study raises the possibility that
measures obtained in serum vs plasma may not repre-
sent the same pool of HMGB1. In addition, it is not
known how plasma or serum levels of HMGB1 relate to
intracellular levels.
In conclusion, higher levels of plasma HMGB1 may
play a role in the development of CVD and high mor-
tality risk in type 1 diabetes and may constitute a spe-
cific target for treatment in these patients. However,
further studies are needed to clarify the determinants of
HMGB1 and the inter-relationship between plasma levels
of HMGB1 and its various receptors and their associations
with CVD.
Fig. 1 Cumulative hazard for fatal and non-fatal CVD (a) and all-
cause mortality (b) across tertiles of plasma HMGB1. Data are adjusted
for age, sex, case–control status, duration of diabetes, HbA1c, smoking
status, MAP, BMI, total cholesterol, use of anti-hypertensive treatment
and continuation of medication use at baseline examination. Compared
with patients in the lowest tertile of HMGB1 (grey line), those in the
middle (dotted line) and highest (black line) tertiles had increased risk
for fatal and non-fatal CVD (HR 1.18 [95% CI 0.68, 2.05] and HR 1.29
[0.73, 2.28]), respectively, p for trend00.337 and all-cause mortality
(HR 1.28 [95% CI 0.70, 2.33] and 2.05 [1.14, 3.67], respectively, p for
trend00.018)
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